Guideline adherence in medication management of psychotic disorders: An observational multisite hospital study

Acta Psychiatrica Scandinavica

Volumn 112, Issue 1, 2005, Pages 18-25

  Weinmann, Stefan ^a   Janssen, B ^a   Gaebel, W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antipsychotic agents; Process assessment; Quality of health care; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DELUSION; DEPRESSION; DISEASE SEVERITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERMANY; GUILT; HEALTH CARE QUALITY; HOSPITAL CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OBSERVATION; OUTCOMES RESEARCH; PARANOID PSYCHOSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RIGOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL INTERACTION; SOCIOECONOMICS; TARDIVE DYSKINESIA; THOUGHT DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GERMANY; GUIDELINES; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MENTAL HEALTH SERVICES; OBSERVATION; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PSYCHOTIC DISORDERS; QUALITY ASSURANCE, HEALTH CARE; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 21044433228     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2005.00547.x     Document Type: Article

References (24)

1. HERMANN RC, PALMER RH. Common ground: a framework for selecting core quality measures for mental health and substance abuse care. Psychiatr Serv 2002;53:281-287.
2. LESLIE DL, ROSENHECK RA. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the department of veterans affairs and the private sector. J Ment Health Policy Econ 2003;6:113-121.
3. HERMANN RC, FINNERTY M, PROVOST S et al. Process measures for the assessment and improvement of quality of care for schizophrenia. Schizophr Bull 2002;28:95-104.
4. POPKIN MK, CALLIES AL, LURIE N et al. An instrument to evaluate the process of psychiatric care in ambulatory settings. Psychiatr Serv 1997;48:524-527.
5. YOUNG AS, SULLIVAN G, BURNAM MA, BROOK RH. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry 1998;55:611-617.
6. MILLER AL, CRISMON ML, RUSH AJ et al. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 2004;30:627-647.
7. MARTIN K, BÉGAUD B, VERDOUX H, LECHEVALLIER N, LATRY P, MOORE N. Patterns of risperidone prescription: a utilization study in south-west France. Acta Psychiatr Scand 2004;109:202-206.
8. KAY SR. Positive and negative syndromes in schizophrenia. New York: Brunner and Mazel, 1991.
9. GUY W. ECDU assessment manual for psychopharmacology. DHEW Publication 76338. Rockville, MD: National Institute of Mental Health, 1976:218-222.
10. STARTUP M, JACKSON MC, BENDIX S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol 2002;41:417-422.
11. DOTES. Dosage record and treatment emergent symptom scale. In: GUY W, ed. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:223-244.
12. LEHMAN AF, STEINWACHS DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10.
13. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl.):1-63.
14. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 1998.
15. BALDESSARINI RJ, TARAZI FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: HARDMAN JG, LIMBIRD LE, GILMAN AG, eds. Goodman and Gilman's the pharmacologic basis of therapeutics. New York: McGraw-Hill, 2001:485-520.
16. WOODS SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
17. DAVIS JM, CHEN N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208.
18. SERNYAK MJ, DAUSEY D, DESAI R, ROSENHECK R. Prescribes' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv 2003;54:246-248.
19. VAN PUTTEN T, MARSHALL BD, LIBERMAN R et al. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993;29:315-320.
20. KANE J, HONIGFELD G, SINGER J, MELTZER H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
21. CHAKOS M, LIEBERMAN J, HOFFMAN E et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526.
22. SOHLER NL, WALKUP J, MCALPINE D et al. Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatr Serv 2003;54:1258-1263.
23. OWEN RR, THRUSH CR, KIRCHNER JE et al. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. Int J Qual Health Care 2000; 12:475-482.
24. SARTORIUS N. Iatrogenic stigma of mental illness. BMJ 2002;324:1470-1471.